A new way of tackling ROP

Article

A potential new treatment approach for retinopathy of prematurity (ROP) may be possible now that insulin-like growth factor binding protein 3 (IGFBP-3) has been found to play an important role in promoting the development of retinal blood vessels.

A potential new treatment approach for retinopathy of prematurity (ROP) may be possible now that insulin-like growth factor binding protein 3 (IGFBP-3) has been found to play an important role in promoting the development of retinal blood vessels, according to researchers from the University of Florida and Harvard Medical School, USA.

IGFBP-3 was already known to play a vital role in the development of various body tissues but, a study led by Maria Grant, MD of the University of Florida found that the protein also activates stem cells and other reparative cells of bone marrow and the lining of blood vessels. The research team infused IGFBP-3 into one eye of nine mice and then placed the mice into a high-oxygen chamber. It was found that the eyes treated with the protein demonstrated more normal retinal blood vessel development.

In a prospective study conducted by Harvard Medical School, it was found that IGFBP-3 levels were lower in infants with ROP than in healthy children, suggesting that the protein helps prevent oxygen-induced blood vessel loss and promotes vascular re-growth.

A study is now being conducted to evaluate whether IGFBP-3, used in conjunction with IGF-1, can help prevent ROP in infants.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.